Skip to content

Cannabis research published in 2022

Page 3 of 7: studies 41 to 60 of 133, newest first. Back to the cannabis overview

Studies

A neuropsychological approach to differentiating cannabis‐induced and primary psychotic disorders

Early Intervention in Psychiatry August 10, 2022 Stephanie M. Woolridge, Chelsea Wood‐Ross, Rohit Voleti et al. 5 citations

AIM: Rates of cannabis use are elevated in early psychosis populations, rendering it difficult to determine if an episode of psychosis is related to cannabis use (e.g., cannabis-induced psychosis), or if substance use is co-occurring with a primary psychotic disorder (e.g., schizophrenia). Clinical presentations of these disorders are often indistinguishable, hindering assessment and treatment....

Differences in clinical features associated with cannabis intoxication in presentations to European emergency departments according to patient age and sex.

Clinical Toxicology August 2022 Yasmin Schmid, Miguel Galicia, Severin B Vogt et al.

To investigate if clinical features associated with acute cannabis intoxication in patients presenting to Emergency Departments for medical assistance differ according to patient age and sex. We analysed presentations in the Euro-DEN Plus dataset from 2014 to 2019 in which cannabis was the only drug involved (except for alcohol), and age, sex and alcohol co-ingestion had been recorded. Age was...

Associations Between Canada's Cannabis Legalization and Emergency Department Presentations for Transient Cannabis-Induced Psychosis and Schizophrenia Conditions: Ontario and Alberta, 2015–2019

The Canadian Journal of Psychiatry August 1, 2022 Russell C. Callaghan, Marcos Sanches, Robin Murray et al.

Objective Cannabis legalization in many jurisdictions worldwide has raised concerns that such legislation might increase the burden of transient and persistent psychotic illnesses in society. Our study aimed to address this issue. Methods Drawing upon emergency department (ED) presentations aggregated across Alberta and Ontario, Canada records (April 1, 2015–December 31, 2019), we employed...

Chronic use of cannabis might impair sensory error processing in the cerebellum through endocannabinoid dysregulation.

Addictive Behaviors August 2022 Adrián F Amil, Belén Rubio Ballester, Martina Maier et al.

Chronic use of cannabis leads to both motor deficits and the downregulation of CB1 receptors (CB1R) in the cerebellum. In turn, cerebellar damage is often related to impairments in motor learning and control. Further, a recent motor learning task that measures cerebellar-dependent adaptation has been shown to distinguish well between healthy subjects and chronic cannabis users. Thus, the...

DOI: 10.1016/j.addbeh.2022.107297 (opens in new tab) Full text (opens in new tab) Cerebellum Chronic cannabis use Endocannabinoid system Error processing +1

Review of delta‐8‐tetrahydrocannabinol (Δ8‐THC): Comparative pharmacology with Δ9‐THC

British Journal of Pharmacology August 1, 2022 Michael Tagen, Linda E. Klumpers

The use of the intoxicating cannabinoid delta‐8‐tetrahydrocannabinol (Δ8‐THC) has grown rapidly over the last several years. There have been dozens of Δ8‐THC studies dating back over many decades, yet no review articles have comprehensively covered these findings. In this review, we summarize the pharmacological studies of Δ8‐THC, including receptor binding, cell signalling, in vivo...

The Effects of Cannabidiol and δ-9-Tetrahydrocannabinol in Social Cognition: A Naturalistic Controlled Study

Cannabis and Cannabinoid Research July 26, 2022 Alberto Sainz-Cort, Daniel Jiménez‐garrido, Elena Muñoz Marrón et al. 9 citations

Background: Social cognition abilities such as empathy and the Theory of Mind (ToM) have been shown to be impaired in neuropsychiatric conditions such as psychotic, autistic, and bipolar disorders. The endocannabinoid system (ECS) seems to play a role in social behavior and emotional processing while it also seems to play a role in those neuropsychiatric conditions showing social cognition...

White Matter Microstructure and Gray Matter Volume in Cannabis-Induced Psychosis and Schizophrenia With Cannabis Use.

The Journal of Neuropsychiatry and Clinical Neurosciences July 25, 2022 Raghav Shah, Abhishek Ghosh, A. Avasthi et al.

OBJECTIVE This study explored the differences in white matter (WM) microstructural integrity and gray matter (GM) volume between cannabis-induced psychosis (CIP) and schizophrenia with cannabis use (SZC). METHODS This cross-sectional study with convenience sampling involved three groups of 20 participants each (CIP, SZC, and a control group without substance use), matched on age, handedness,...

RETRACTED: A vulnerable young adult using cannabis for therapeutic purposes despite emerging psychosis

Psychiatry Research Case Reports July 23, 2022 Jill M. Williams, Mary Barna Bridgeman, Lisa Laitman Retracted

There is widespread support of cannabis for therapeutic purposes (CTP) despite lack of federal oversight and inconsistencies in screening, consenting, and authorizing use. Young people may have increased vulnerability to adverse effects including psychosis, substance use disorder, reduced academic achievement or other symptoms. We describe a case of a 20 year old who was prescribed CTP in the...

Drug Misuse

July 22, 2022

The word ‘misuse’ as used in many Anglophone countries signifies the non-authorised use of medicines that can, in appropriate circumstances, be legally used. By contrast, The World Health Organization prefers the term ‘abuse’. Depending on the jurisdiction, the substances in question are referred to as either scheduled or controlled drugs. Overall drug use by adults in England and Wales has...

Prenatal Δ9-Tetrahydrocannabinol Exposure in Males Leads to Motivational Disturbances Related to Striatal Epigenetic Dysregulation.

Biological Psychiatry July 15, 2022 Randall J Ellis, Anissa Bara, Claudia A Vargas et al.

Cannabis remains one of the most widely abused drugs during pregnancy. In utero exposure to its principal psychoactive component, Δ9-tetrahydrocannabinol (THC), can result in long-term neuropsychiatric risk for the progeny. This study investigated epigenetic signatures underlying these enduring consequences. Rat dams were exposed daily to THC (0.15 mg/kg) during pregnancy, and adult male...

Self-treatment of psychosis and complex post-traumatic stress disorder with LSD and DMT—A retrospective case study

Psychiatry Research Case Reports July 15, 2022 Mika Turkia 14 citations

This article describes a case of a teenager with early complex trauma due to chronic domestic violence. Cannabis use triggered auditory hallucinations, after which the teenager was diagnosed with an acute schizophrenia-like psychotic disorder. Antipsychotic medication did not fully resolve symptoms. Eventually the teenager chose to self-medicate with LSD in order to resolve a suicidal...

DOI: 10.1016/j.psycr.2022.100029 (opens in new tab) Cannabis Psychosis Antipsychotic Schizophrenia object-oriented programming +2

Cannabis’s Link to Schizotypy: Phenomenon, Measurement Bias, or Delusion?

Cannabis July 11, 2022 Brianna R. Altman, Mitch Earleywine, Maha N. Mian et al.

Links between cannabis use and psychosis generate research and media attention. Cannabis users have outscored non-users on the Schizotypal Personality Questionnaire-Brief (SPQ-B) in multiple studies, but previous work suggests that groups do not differ if biased items are removed. The present study examined links between schizotypal personality and cannabis use in a large sample recruited from...

DOI: 10.26828/cannabis/2022.02.003 (opens in new tab) Cannabis Schizotypy Psychopathology Psychosis +4

Expectancies for Cannabis-Induced Emotional Breakthrough, Mystical Experiences and Changes in Dysfunctional Attitudes: Perceptions of the Potential for Cannabis-Assisted Psychotherapy for Depression

Cannabis July 11, 2022 Mitch Earleywine, Maha N. Mian, Brianna R. Altman et al. 11 citations

Psychedelic-assisted psychotherapy has established antidepressant effects. Cannabis users appear to expect high doses administered in a session much like psychedelic-assisted psychotherapy to create comparable subjective effects. The current studies explored expectations of antidepressant effects of such cannabis-assisted sessions to replicate and extend previous work. Users not only expected a...

Changes in striatal dopamine release, sleep, and behavior during spontaneous Δ-9-tetrahydrocannabinol abstinence in male and female mice.

Neuropsychopharmacology July 2022 Andrew J Kesner, Yolanda Mateo, Karina P Abrahao et al.

Withdrawal symptoms are observed upon cessation of cannabis use in humans. Although animal studies have examined withdrawal symptoms following exposure to delta-9-tetrahydrocannabinol (THC), difficulties in obtaining objective measures of spontaneous withdrawal using paradigms that mimic cessation of use in humans have slowed research. The neuromodulator dopamine (DA) is affected by chronic THC...

Differences in Inhibitory Control and Resting Brain Metabolism between Older Chronic Users of Tetrahydrocannabinol (THC) or Cannabidiol (CBD)—A Pilot Study

Brain Sciences June 23, 2022 Thorsten Rudroff, Craig D. Workman, Phillip E. Gander et al. 3 citations

Δ9-Tetrahydrocannabinol is the main psychoactive component of cannabis and cannabidiol is purportedly responsible for many of the medicinal benefits. The effects of Δ9-tetrahydrocannabinol and cannabidiol in younger populations have been well studied; however, motor function, cognitive function, and cerebral glucose metabolism in older adults have not been extensively researched. The purpose of...

Applying Lessons From Cannabis to the Psychedelic Highway

JAMA Health Forum June 17, 2022 Kevin F. Boehnke, Alan K. Davis, Jenna McAfee 20 citations

In 2020, Oregon became the first state in the US to decriminalize use of many illicit substances, including mushrooms containing psilocybin, and allow adults aged 21 years and older to take psilocybin under supervision in state-licensed service centers.Numerous states and municipalities have since proposed similar policies, 1 a process catalyzed by excitement about positive clinical trials of...

Weed Light: An Exploratory Study of Delta-8 THC Conversations on Reddit

June 8, 2022 Szczypka Glen, Jessica K. Pepper, Annice Kim

Delta-8 tetrahydrocannabinol (THC) is a newly popular cannabinoid that can be purchased easily at gas stations, vape shops, and online retailers in most regions of the United States. The US Food and Drug Administration (FDA) has expressed the need for novel data sources to understand the use of products like Delta-8 and rapidly detect potential safety issues. Using social media platform Reddit,...

Cannabis use and cognitive impairment in schizophrenia

European Psychiatry June 1, 2022 M. Gonçalves, J. Romão, R. André et al.

Introduction Neurocognitive deficits amongst patients with schizophrenia are considered one of schizophrenia’s central features. These deficits appear to be present from the first episode of psychosis (FEP) and certain cognitive impairments could be components of a genetic vulnerability to schizophrenia. Regarding research on cannabis and cognition in schizophrenia, different studies have...

Immune regulatory gene polymorphisms, frequent cannabis use, and psychosis: implications to Treg hypofunction

European Psychiatry June 1, 2022 Fabiana Corsi-Zuelli, C. Loureiro, Rosana Shuhama et al.

Introduction We have previously shown that the association between frequent cannabis use and psychosis is more likely in subgroups with low-grade inflammation than subgroups without (PMID: 33736715). The role of immune-related polymorphisms remains unknown. Objectives To explore whether polymorphisms affecting the function of key immune regulatory proteins moderate the association between...

Is Cannabis Abstinence Related to Subsequent Reduced Risk of Psychosis? a Nested Retrospective Case Control Hierarchical Survival Analysis

BJPsych Open June 1, 2022 Rafael Gafoor

Aims There is strong evidence from systematic reviews and meta-analyses that cannabis use is related to an elevated risk of developing a subsequent psychotic illness. It is less clear if the length of cannabis abstinence is related to the risk of developing a psychotic episode. We explore the relationship between length of cannabis abstinence and subsequent risk of a psychotic episode. Methods...